142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in Arvinas, Inc. (NASDAQ:ARVN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 142,214 shares of the company’s stock, valued at approximately $1,182,000. GSA Capital Partners LLP owned approximately 0.22% of Arvinas at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Armistice Capital LLC raised its stake in shares of Arvinas by 50.0% in the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after acquiring an additional 600,000 shares during the last quarter. TCG Crossover Management LLC acquired a new position in shares of Arvinas during the third quarter valued at $13,780,000. Qube Research & Technologies Ltd boosted its stake in shares of Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock valued at $12,668,000 after purchasing an additional 903,337 shares during the last quarter. Millennium Management LLC boosted its stake in Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after acquiring an additional 885,483 shares during the last quarter. Finally, Balyasny Asset Management L.P. grew its stake in shares of Arvinas by 469.1% during the third quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock worth $10,286,000 after purchasing an additional 995,125 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Price Performance

Arvinas stock opened at $9.20 on Tuesday. The firm has a market cap of $593.59 million, a PE ratio of 92.01 and a beta of 1.71. The stock’s fifty day moving average price is $8.20 and its two-hundred day moving average price is $10.06. Arvinas, Inc. has a one year low of $6.95 and a one year high of $14.51.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of ($0.37) by $2.95. Arvinas had a net margin of 2.94% and a return on equity of 1.91%. The business had revenue of $249.70 million during the quarter, compared to analysts’ expectations of $60.71 million. During the same quarter in the prior year, the business posted ($0.84) earnings per share. Arvinas’s revenue was up 1014.7% compared to the same quarter last year. Sell-side analysts expect that Arvinas, Inc. will post -0.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Arvinas

In related news, CFO Andrew Saik sold 5,696 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total value of $46,479.36. Following the sale, the chief financial officer directly owned 187,432 shares of the company’s stock, valued at $1,529,445.12. This trade represents a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ARVN shares. Wall Street Zen upgraded shares of Arvinas from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded Arvinas from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. BTIG Research restated a “buy” rating and set a $18.00 price objective on shares of Arvinas in a research note on Tuesday, August 4th. Wedbush raised their target price on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $11.00 price target (down from $15.00) on shares of Arvinas in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $14.17.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.